Loading
A phase 1/2 trial of Pembrolizumab in non-small-cell lung cancer and small-cell lung cancer, run by Tango Therapeutics, Inc., active and no longer recruiting.
Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors is a phase 1/2 interventional study registered as NCT05887492 by Tango Therapeutics, Inc., with 126 participants planned, started 2023-06-12 and due to reach its primary completion in 2026-09. Interventions recorded: TNG260, Pembrolizumab. Conditions listed: Non Small Cell Lung Cancer, Solid Tumors, Adult, Lung Cancer, Lung Adenocarcinoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Tango Therapeutics, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Tango Therapeutics, Pembrolizumab.
Shares STK11, Small-cell lung cancer, Non-small-cell lung cancer.
Shares STK11, Pembrolizumab, Non-small-cell lung cancer.
Shares STK11, Non-small-cell lung cancer.
Shares STK11, Pembrolizumab, Non-small-cell lung cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/